Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of intravenous fixed-dose tiragolumab + atezolizumab in advanced solid tumors
2022-001157-23Phase 2Active
- Sponsor
- Roche
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tiragolumab and atezolizumab in Nonhematologic neoplasms, sponsored by Roche. Primary endpoint: Incidence and severity of adverse events. Started Nov 2022; status: active.
02
Drugs
tiragolumabatezolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2022-001157-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001157-23.